Literature DB >> 23524331

Brain atrophy and lesion load predict long term disability in multiple sclerosis.

Veronica Popescu1, Federica Agosta, Hanneke E Hulst, Ingrid C Sluimer, Dirk L Knol, Maria Pia Sormani, Christian Enzinger, Stefan Ropele, Julio Alonso, Jaume Sastre-Garriga, Alex Rovira, Xavier Montalban, Benedetta Bodini, Olga Ciccarelli, Zhaleh Khaleeli, Declan T Chard, Lucy Matthews, Jaqueline Palace, Antonio Giorgio, Nicola De Stefano, Philipp Eisele, Achim Gass, Chris H Polman, Bernard M J Uitdehaag, Maria Jose Messina, Giancarlo Comi, Massimo Filippi, Frederik Barkhof, Hugo Vrenken.   

Abstract

OBJECTIVE: To determine whether brain atrophy and lesion volumes predict subsequent 10 year clinical evolution in multiple sclerosis (MS).
DESIGN: From eight MAGNIMS (MAGNetic resonance Imaging in MS) centres, we retrospectively included 261 MS patients with MR imaging at baseline and after 1-2 years, and Expanded Disability Status Scale (EDSS) scoring at baseline and after 10 years. Annualised whole brain atrophy, central brain atrophy rates and T2 lesion volumes were calculated. Patients were categorised by baseline diagnosis as primary progressive MS (n=77), clinically isolated syndromes (n=18), relapsing-remitting MS (n=97) and secondary progressive MS (n=69). Relapse onset patients were classified as minimally impaired (EDSS=0-3.5, n=111) or moderately impaired (EDSS=4-6, n=55) according to their baseline disability (and regardless of disease type). Linear regression models tested whether whole brain and central atrophy, lesion volumes at baseline, follow-up and lesion volume change predicted 10 year EDSS and MS Severity Scale scores.
RESULTS: In the whole patient group, whole brain and central atrophy predicted EDSS at 10 years, corrected for imaging protocol, baseline EDSS and disease modifying treatment. The combined model with central atrophy and lesion volume change as MRI predictors predicted 10 year EDSS with R(2)=0.74 in the whole group and R(2)=0.72 in the relapse onset group. In subgroups, central atrophy was predictive in the minimally impaired relapse onset patients (R(2)=0.68), lesion volumes in moderately impaired relapse onset patients (R(2)=0.21) and whole brain atrophy in primary progressive MS (R(2)=0.34).
CONCLUSIONS: This large multicentre study points to the complementary predictive value of atrophy and lesion volumes for predicting long term disability in MS.

Entities:  

Keywords:  MRI; MULTIPLE SCLEROSIS

Mesh:

Year:  2013        PMID: 23524331     DOI: 10.1136/jnnp-2012-304094

Source DB:  PubMed          Journal:  J Neurol Neurosurg Psychiatry        ISSN: 0022-3050            Impact factor:   10.154


  113 in total

Review 1.  Evidence-based guidelines: MAGNIMS consensus guidelines on the use of MRI in multiple sclerosis--establishing disease prognosis and monitoring patients.

Authors:  Mike P Wattjes; Àlex Rovira; David Miller; Tarek A Yousry; Maria P Sormani; Maria P de Stefano; Mar Tintoré; Cristina Auger; Carmen Tur; Massimo Filippi; Maria A Rocca; Franz Fazekas; Ludwig Kappos; Chris Polman
Journal:  Nat Rev Neurol       Date:  2015-09-15       Impact factor: 42.937

2.  Disease-modifying therapies modulate retinal atrophy in multiple sclerosis: A retrospective study.

Authors:  Julia Button; Omar Al-Louzi; Andrew Lang; Pavan Bhargava; Scott D Newsome; Teresa Frohman; Laura J Balcer; Elliot M Frohman; Jerry Prince; Peter A Calabresi; Shiv Saidha
Journal:  Neurology       Date:  2017-01-11       Impact factor: 9.910

Review 3.  MRI in the assessment and monitoring of multiple sclerosis: an update on best practice.

Authors:  Ulrike W Kaunzner; Susan A Gauthier
Journal:  Ther Adv Neurol Disord       Date:  2017-05-12       Impact factor: 6.570

4.  Putaminal alteration in multiple sclerosis patients with spinal cord lesions.

Authors:  Hilga Zimmermann; Hans O Rolfsnes; Swantje Montag; Janine Wilting; Amgad Droby; Eva Reuter; Joachim Gawehn; Frauke Zipp; Adriane Gröger
Journal:  J Neural Transm (Vienna)       Date:  2015-05-14       Impact factor: 3.575

Review 5.  Preventing disability in inflammatory bowel disease.

Authors:  Patrick B Allen; Corinne Gower-Rousseau; Silvio Danese; Laurent Peyrin-Biroulet
Journal:  Therap Adv Gastroenterol       Date:  2017-10-16       Impact factor: 4.409

Review 6.  Clinical relevance of brain volume measures in multiple sclerosis.

Authors:  Nicola De Stefano; Laura Airas; Nikolaos Grigoriadis; Heinrich P Mattle; Jonathan O'Riordan; Celia Oreja-Guevara; Finn Sellebjerg; Bruno Stankoff; Agata Walczak; Heinz Wiendl; Bernd C Kieseier
Journal:  CNS Drugs       Date:  2014-02       Impact factor: 5.749

7.  MRI biomarkers of disease progression in multiple sclerosis: old dog, new tricks?

Authors:  Yael Barnett; Justin Y Garber; Michael H Barnett
Journal:  Quant Imaging Med Surg       Date:  2020-02

8.  Know your tools--concordance of different methods for measuring brain volume change after ischemic stroke.

Authors:  Nawaf Yassi; Bruce C V Campbell; Bradford A Moffat; Christopher Steward; Leonid Churilov; Mark W Parsons; Patricia M Desmond; Stephen M Davis; Andrew Bivard
Journal:  Neuroradiology       Date:  2015-04-08       Impact factor: 2.804

9.  Learning joint segmentation of tissues and brain lesions from task-specific hetero-modal domain-shifted datasets.

Authors:  Reuben Dorent; Thomas Booth; Wenqi Li; Carole H Sudre; Sina Kafiabadi; Jorge Cardoso; Sebastien Ourselin; Tom Vercauteren
Journal:  Med Image Anal       Date:  2020-10-09       Impact factor: 8.545

10.  Atrophied Brain T2 Lesion Volume at MRI Is Associated with Disability Progression and Conversion to Secondary Progressive Multiple Sclerosis.

Authors:  Antonia Valentina Genovese; Jesper Hagemeier; Niels Bergsland; Dejan Jakimovski; Michael G Dwyer; Deepa P Ramasamy; Alexis A Lizarraga; David Hojnacki; Channa Kolb; Bianca Weinstock-Guttman; Robert Zivadinov
Journal:  Radiology       Date:  2019-09-24       Impact factor: 11.105

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.